Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minute Insight: SonALAsense MR-Guided Ultrasound Drug-Device Combo Trials Get Green Light

Executive Summary

SonALAsense has received Safe to Proceed letters from the FDA to begin trials of its ultrasound-activated cancer killing drug.

You may also be interested in...



Global Approvals Analysis: Eight Brain Device Approvals Mark Neurotech November

Medtech Insight's Approvals Tracker reports 22 medical device approvals from outside the United States in November, including 12 CE marks from Europe, plus approvals from Taiwan, Singapore, Japan, India, Canada, Australia and Argentina.

Deals Shaping The Medical Industry, July 2022

In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in July 2022. Data provided by Biomedtracker.

French Medtech System ‘Too Rigorous’ For Innovation To Flourish, Argues Healthtech Expert

David Caumartin is well versed in the both the benefits and drawbacks of being a France-based medtech innovator, having spent almost three decades in the local industry. The VP of France Biotech spoke to Medtech Insight about the new opportunities there to be seized, and the pitfalls to avoid.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT145564

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel